Lechebnye effekty gormonal'nykh kontratseptivov (obzor literatury)

Full Text


About the authors

N M Podzolkova

V V Korennaya


  1. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004; (Suppl. 4), 190: 5-22.
  2. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-91.
  3. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000; 355: 922-4.
  4. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-caontaining low-dose oral contraceptive. Contraception 2002; 66: 393-9.
  5. Winkler UH, Ferguson H, Mulders J. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 µg ethinylestradiol. Contraception 2004; 69: 469-76.
  6. Davis A, Godwin A, Lippman J et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96: 913-20.
  7. Reid RL. (2004) Premenstrual syndrome. http://www.endotext.org/female/female10/femaleframe10.htm
  8. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-9.
  9. Borenstein J, Yu H-T, Wade S et al. Effect on an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health related quality of life. J Reprod Med 2002; 48: 79-85.
  10. Prentice A. Endometriosis. BMJ 2001; 323: 93-5.
  11. Vercellini P, Fedele L, Pietropaolo G et al. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003; 9: 387-96.
  12. Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis (Cochrane Review). In the Cochrane Library, Oxford, Issue 1. Oxford: Update Software, 2003.
  13. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). In the Cochrane Library, Oxford, Issue 1. Oxford: Update Software, 2003.
  14. Vercellini P, Frontino G, De Giorgi O et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Fertil Steri 2003; 80: 560-3.
  15. Meresman GF, Augé L, Barañao RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril 2002; 77: 1141-7.
  16. Cosson M, Querleu D, Donnez J et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77: 684-92.
  17. Vercellini P, De Giorgi O, Mosconi P et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52-61.
  18. Fedele L, Bianchi S, Zanconato G et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485-8.
  19. The Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis. Guideline 2000; 24.
  20. Thiboutot D, Archer DF, Lemay A et al. A randomized, controlled trial of a low-dose contraceptive containing 20 mg of ethinyl estradiol and 100 mg of levonorgestrel for acne treatment. Fertil Steril 2001; 76: 461-8.
  21. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004, CD004425.
  22. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726-35.
  23. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003, CD001125.
  24. Petitti DB, Piaggio G, Mehta S et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 2000; 95: 736-44.
  25. Kuohung W, Borga TTA, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based approach. Contraception 2000; 61: 77-8.
  26. Reed SD, Scholes D, LaCroix AZ et al. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 2003; 68: 177-82.
  27. Nappi C, Di Spiezio Sardo A, Acunzo G et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003; 67: 355-59.
  28. Endrikat J, Mih E, Dusterberg K et al. A 3-year double-blind randomized controlled study on the influence of two oral contraceptives containing either 20 µg or 30 µg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 2004; 69: 179-87.
  29. Castelo-Branco C, Vicente JJ, Pons F et al. Bone mineral density in young, hypothalamic oligomenorrheic women treated with oral contraceptives. J Reprod Med 2001; 46: 875-79.
  30. Gordon CM, Grace E, Emans SJ et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa. J Clin Endocrinol Metab 2002; 87: 4935-41.
  31. Munoz MT, Morande G, Garcia-Centenera JA et al. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 2002; 146: 45-50.
  32. Grinspoon S, Thomas L, Miller K et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002; 87: 2883-91.
  33. Reproductive Health and Research World Health Organization. Improving access to quality care in family planning. Medical eligibilty criteria for contraceptive use. World Health Organization. Geneva, 2004.
  34. Burkman RT, Collins JA, Schulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001; 185: 4-12.
  35. Wise LA, Palmer JR, Harlow BL et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159: 113-23.
  36. Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women aged 25-40 years. Acta Obstet Gynecol Scand 2000; 79: 202-7.
  37. Westhoff C, Britton JA, Gammon MD et al. Oral contraceptives and benign ovarian tumours. Am J Epidemiol 2000; 152: 242-6.
  38. The ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16: 1527-35.



Abstract: 57

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies